Thiryayi S A, Low Y X, Shelton D, Narine N, Slater D, Rana D N
Manchester Cytology Centre, Manchester Royal Infirmary, Manchester, UK.
Cytopathology. 2018 Aug;29(4):343-348. doi: 10.1111/cyt.12557. Epub 2018 May 24.
To assess our practice using the recently developed standardised classification system designated The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) and to ascertain the rates of malignancy for each category by means of a retrospective study.
All salivary gland FNAC samples received between 1 January 2013 and 31 December 2015 were retrospectively assigned a diagnostic category code from the MSRSGC. Cytology results were correlated with subsequent histology (where available), and clinical and radiological follow up.
A total of 287 salivary gland FNA samples were received from 272 patients. The specimens were classified as non-diagnostic (21.3%), non-neoplastic (22%), atypia of undetermined significance (2.4%), neoplasm benign (36.9%), neoplasm of uncertain malignant potential (5.2%), suspicious for malignancy (1.7%) and malignant (10.5%; low grade 1.4% and high grade 9.1%). Histological and clinical/radiological follow up was available for 138 (48.1%) specimens, clinical/radiological follow up only for 145 (50.5%) and no follow up for the remaining four (1.4%) samples. The risk of malignancy for each category was non-diagnostic (8.5%), non-neoplastic (1.6%), atypia of undetermined significance (0%), neoplasm benign (1.9%), neoplasm of uncertain malignant potential (26.7%), suspicious for malignancy (100%) and malignant (100%).
The MSRSGC appears to be a useful tool to guide clinical management and provide an indication of possible risk of malignancy. We favour implementing use of these categories in our reporting practice with a future re-evaluation to assess maintenance of service quality as well as the clinical utility of this reporting system.
采用最近开发的标准化分类系统——米兰唾液腺细胞病理学报告系统(MSRSGC)来评估我们的实践,并通过回顾性研究确定每个类别的恶性肿瘤发生率。
对2013年1月1日至2015年12月31日期间接收的所有唾液腺细针穿刺抽吸活检(FNAC)样本,回顾性地根据MSRSGC指定一个诊断类别代码。细胞学结果与随后的组织学结果(如可用)以及临床和放射学随访结果相关联。
共收到来自272例患者的287份唾液腺FNA样本。标本分类为非诊断性(21.3%)、非肿瘤性(22%)、意义未明的非典型性病变(2.4%)、良性肿瘤(36.9%)、恶性潜能不确定的肿瘤(5.2%)、可疑恶性(1.7%)和恶性(10.5%;低级别1.4%,高级别9.1%)。138份(48.1%)标本有组织学及临床/放射学随访结果,145份(50.5%)仅有临床/放射学随访结果,其余4份(1.4%)样本无随访结果。每个类别的恶性风险为:非诊断性(8.5%)、非肿瘤性(1.6%)、意义未明的非典型性病变(0%)、良性肿瘤(1.9%)、恶性潜能不确定的肿瘤(26.7%)、可疑恶性(100%)和恶性(100%)。
MSRSGC似乎是指导临床管理并提供恶性肿瘤可能风险指征的有用工具。我们倾向于在我们的报告实践中采用这些类别,并在未来进行重新评估,以评估服务质量的维持情况以及该报告系统的临床实用性。